Benitec Biopharma (BLT) Short Interest
Benitec Biopharma (ASX:BLT) had 0.01% of shares reported as short positions as of 30 July 2026, representing 45,569 shares. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Benitec Biopharma
Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, focused on developing novel genetic medicines. Its proprietary DNA-directed RNA interference (ddRNAi) platform combines RNA interference with gene therapy to achieve sustained silencing of disease-causing genes with a single administration. The company is advancing ddRNAi-based therapeutics for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD).
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4BLT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Benitec Biopharma
About
website
Be the first to discuss BLT
Start a research thread or post the first pulse update